Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

Novartis EspañaNovartis España
VS
Hikma PharmaceuticalsHikma Pharmaceuticals
Novartis España

Novartis España

Gran Via de les Corts Catalanes, Barcelona, Cataluña, España, 08013, ES

Last Update: 28/10/2025

View Profile
Between 750 and 799
https://www.novartis.es/
756/1000Fair

Novartis está reimaginando la medicina con el fin de mejorar y prolongar la vida de las personas. Como compañía líder mundial en desarrollo de medicamentos, utilizamos la innovación basada en la ciencia y las tecnologías digitales para crear tratamientos transformadores...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:338
Subsidiaries:43
12-month incidents
0
Known data breaches
0
Attack type number
0
Hikma Pharmaceuticals

Hikma Pharmaceuticals

1 New Burlington Place, London, W1S 2HR, GB

Last Update: 03/04/2026

View Profile
Between 750 and 799
http://www.hikma.com
767/1000Fair

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospita...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:10,252
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
Novartis España

Novartis España

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
Hikma Pharmaceuticals

Hikma Pharmaceuticals

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis España in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents

Incident History - Novartis España (X = Date, Y = Severity)

Novartis España cyber incidents detection timeline including parent company and subsidiaries.

R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
Novartis España

Novartis España

Incidents
No explicit notable incidents reported.
Hikma Pharmaceuticals

Hikma Pharmaceuticals

Incidents
No explicit notable incidents reported.

FAQ

Between Novartis España company and Hikma Pharmaceuticals company, which one has the best AI Cybersecurity Score ?
Between Novartis España company and Hikma Pharmaceuticals company, which one has experienced more cyber incidents in the past ?
Between Novartis España company and Hikma Pharmaceuticals company, which one has experienced more cyber incidents this year ?
Between Novartis España company and Hikma Pharmaceuticals company, which one has experienced at least one ransomware attack ?
Between Novartis España company and Hikma Pharmaceuticals company, which one has experienced at least one data breach ?
Between Novartis España company and Hikma Pharmaceuticals company, which one has experienced at least one targeted cyberattack ?
Between Novartis España company and Hikma Pharmaceuticals company, which one has experienced at least one vulnerability ?
Between Novartis España company and Hikma Pharmaceuticals company, which one holds the most compliance certifications ?
Between Novartis España company and Hikma Pharmaceuticals company, which one holds the fewest compliance certifications ?
Between Novartis España company and Hikma Pharmaceuticals company, which one has the most subsidiaries ?
Between Novartis España company and Hikma Pharmaceuticals company, which one has the largest number of employees ?
Between Novartis España and Hikma Pharmaceuticals, which company holds both SOC 2 Type 1 certifications ?
Between Novartis España and Hikma Pharmaceuticals, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - Novartis España or Hikma Pharmaceuticals ?
Which company is PCI DSS compliant - Novartis España or Hikma Pharmaceuticals ?
Between Novartis España and Hikma Pharmaceuticals, which company complies with HIPAA regulations for healthcare data ?
Between Novartis España and Hikma Pharmaceuticals, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-15511
SUMMARY

A vulnerability was determined in Comfast CF-WR631AX V3 up to 2.7.0.8. Affected by this vulnerability is the function system_wl_upload_pic_file of the file /usr/bin/webmgnt of the component FastCGI Backend. This manipulation of the argument filename causes os command injection. It is possible to initiate the attack remotely. The exploit has been publicly disclosed and may be utilized. The vendor was contacted early about this disclosure but did not respond in any way.

PUBLISHED
Date2026-07-12
UPDATED
Date2026-07-12
RISK INFORMATION (Score: 9.8)
CVSS2
Base Score: 10.0
Complexity: LOW
AV:N/AC:L/Au:N/C:C/I:C/A:C
CVSS3
Base Score: 9.8
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
CVSS4
Base Score: 8.9
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
5.9
EXPLOITABILITY
3.9
CVE-2026-15510
SUMMARY

A vulnerability was found in Leantime up to 3.8.0. Affected is the function Setting::saveSetting of the component API. The manipulation results in improper authorization. The attack may be performed from remote. The exploit has been made public and could be used. The vendor was contacted early about this disclosure but did not respond in any way.

PUBLISHED
Date2026-07-12
UPDATED
Date2026-07-12
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-15509
SUMMARY

A vulnerability has been found in Leantime up to 3.8.0. This impacts the function editUser/addUser of the component JSON-RPC Endpoint. The manipulation of the argument role leads to improper authorization. The attack is possible to be carried out remotely. The exploit has been disclosed to the public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

PUBLISHED
Date2026-07-12
UPDATED
Date2026-07-12
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-15508
SUMMARY

A flaw has been found in Helicone ai-gateway up to 0.2.0-beta.30. This affects the function build_target_url of the file ai-gateway/src/dispatcher/service.rs of the component AWS Metadata Service. Executing a manipulation of the argument extracted_path_and_query can lead to server-side request forgery. The attack can be executed remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

PUBLISHED
Date2026-07-12
UPDATED
Date2026-07-12
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-15507
SUMMARY

A vulnerability was detected in coollabsio Coolify up to 4.1.1. The impacted element is an unknown function of the file /app/Policies/ of the component Policy Handler. Performing a manipulation results in missing authorization. Remote exploitation of the attack is possible. The exploit is now public and may be used.

PUBLISHED
Date2026-07-12
UPDATED
Date2026-07-12
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8